To read the full story
Related Article
- Novo Nordisk Logs 3.6% Growth in Japan in 2024, Driven by Semaglutide
April 28, 2025
- Novo Japan Sales Renew Record in 2022 as Ozempic, Rybelsus Blossom
April 12, 2023
- Novo Japan’s Sales Hit 100 Billion Yen Mark in 2021, but President Frets Future Investments
April 21, 2022
- Novo Japan Notches 10% Growth in 2020, President Proud of This Feat amid Market Decline
April 13, 2021
- Novo Japan Chief Sees 100 Billion Yen Target Achievable on Ozempic, Rybelsus
June 30, 2020
BUSINESS
- Japan Pharma Market Grows 1% to Record 11.4 Trillion Yen in FY2024: IQVIA
May 23, 2025
- Tecentriq-Avastin Yields Positive Data on HCC: China/Japan PIII
May 23, 2025
- Meiji, Sandoz Tie-Up to Secure Stable Supply of Antibiotic Intermediates
May 23, 2025
- Camzyos, Tremfya, Tivdak, and More Now Available in Japan
May 22, 2025
- Alloy Japan Now Up and Running to Deliver iCAR-T for Cancer Therapy Development
May 22, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…